View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNext Science 배당 및 자사주 매입배당 기준 점검 0/6Next Science 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-2,398.2%자사주 매입 수익률총 주주 수익률-2,398.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 11Next Science Limited to Report Q1, 2025 Results on Apr 24, 2025Next Science Limited announced that they will report Q1, 2025 results on Apr 24, 2025공시 • Mar 11Next Science Limited, Annual General Meeting, May 09, 2025Next Science Limited, Annual General Meeting, May 09, 2025.공시 • Feb 07Next Science Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Next Science Limited announced that they will report fiscal year 2024 results on Feb 28, 2025공시 • Jan 20Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025Next Science Limited announced that they will report Q4, 2024 results on Jan 23, 2025공시 • Jan 08Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former EmployeeNext Science Limited announced that a former employee, Michael Morello has filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging breaches of fiduciary duties and mismanagement against several employees. Mr. Morello was VP, Wound Care Sales at Next Science LLC until December 2023. In May 2024, Next Science LLC commenced litigation against Mr. Morello and several former employees for breach of post-employment restraints. Mr. Morello's complaint makes several claims including that Next Science's XBIO technology has not been approved by the FDA as a biofilm eradication process and that the Company did not take adequate measures to address safety concerns about the use of its surgical solution XPERIENCETM in breast implant procedures. The Company confirms that the products it sells are safe, effective, approved by the FDA (the US healthcare regulatory authority) and promoted within their FDA approved intended use. The Board is concerned that the Complaint has not been brought in good faith due to the fact that Mr. Morello has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged. Next Science has, in consultation with its insurers, engaged US attorneys in relation to both proceedings and the Company and Next Science LLC will continue to pursue the Non- Compete Action against Mr. Morello and several former employees for the breach of post- employment restraints. Next Science will provide further updates as and when there is material progress in these USA civil proceedings.공시 • Oct 16Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024Next Science Limited announced that they will report Q3, 2024 results on Oct 22, 2024공시 • Jul 26Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024Next Science Limited announced that they will report first half, 2024 results on Aug 30, 2024공시 • Jul 10Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024Next Science Limited announced that they will report Q2, 2024 results on Jul 25, 2024공시 • Apr 23Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024Next Science Limited announced that they will report Q1, 2024 results on Apr 24, 2024공시 • Mar 04Next Science Limited, Annual General Meeting, May 03, 2024Next Science Limited, Annual General Meeting, May 03, 2024, at 10:01 E. Australia Standard Time.공시 • Feb 16Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024Next Science Limited announced that they will report fiscal year 2023 results on Feb 28, 2024공시 • Nov 01Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,571,429 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,851,024 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,244,504 Price\Range: AUD 0.42 Transaction Features: Reserved Share Offering; Subsequent Direct Listing공시 • Oct 24Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive DirectorNext Science Limited announced the appointment of Ms. Katherine Ostin as an independent Non Executive Director of the Company and Chair of the Board’s Audit and Risk Committee with effect from 24 October 2023. Ms. Ostin is an experienced non-executive director and audit and risk committee chair. Ms. Ostin’s appointment strengthens the Board’s skills in a number of key areas including finance and accounting, audit, risk, governance, strategy and business development. Ms. Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in the aged care and healthcare sectors, having established and led KPMG’s New South Wales Health, Ageing and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms. Ostin worked in Australia, the US, Asia, and the UK. Ms. Ostin currently serves as a Non-Executive Director of 3P Learning Limited, dusk Group Limited, Capral Limited and Alex Corporation Limited. She holds a Bachelor of Commerce (Accounting and Finance) from the University of New South Wales and is a Fellow of the Financial Services Institute of Australasia. Ms. Ostin is also a graduate of the Australian Institute of Company Directors (AICD).공시 • Aug 23Next Science Limited Announces Board ChangesNext Science Limited announced the appointment of Ms. Aileen Stockburger as Chair of the Next Science Board of Directors and the appointment of a long standing advisor to the Company, Mr. Grant Hummel, as an independent Non-Executive Director, effective 23 August 2023, further strengthening the skills of the Board in a number of key areas including strategy, financial acumen, legal and governance. The timing of the Board changes has been brought about following the retirement of Mr. Mark Compton AM as Chair of the Company. Mr. Compton’s retirement from the Board follows two recent close family bereavements and his need to take some personal time. Aileen Stockburger has been an independent Non-Executive Director of the Company since 2018, having joined ahead of the Company’s admission to ASX. Ms Stockburger was most recently re-elected by shareholders at the Company’s 2023 Annual General Meeting. Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Ms Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania and is a Certified Public Accountant (CPA USA). She is a Non-Executive Director of Microbot Medical and two private equity companies - Orchid Orthopaedic Solutions and Materna Medical. Ms Stockburger is also a graduate of the Australian Institute of Company Directors (AICD). Grant Hummel was part of the Company’s initial public offering (IPO) and ASX listing deal team in 2019. Mr. Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr. Hummel has been a non-executive director of GLG Corp. Ltd. since 2018 and serves as the Chair of GLG’s Nomination and Remuneration Committee and as a member of GLG’s Audit and Risk Committee. Mr. Hummel holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. He also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan). Mr. Hummel has also been appointed as a member of the Board's Audit and Risk Committee and People, Culture and Remuneration Committee. Ms. Stockburger will remain as Chair of the Board's Audit and Risk Committee and independent Non-Executive Director, Mr. DanSpira, will continue to Chair the Board's People, Culture and Remuneration Committee. The Board will continue its ongoing search for at least one new independent non-executive director who may be US based.공시 • Jun 30+ 1 more updateNext Science Limited Appoints Marc Zimmerman as Chief Financial OfficerThe Board of Next Science Limited appointment and commencement of Marc Zimmerman as Chief Financial Officer.공시 • Jun 29Next Science Limited Commercialising Its Proprietary Xbiotm Suite of ProductsNext Science Limited announced commercialising its proprietary XBIOTM suite of products to reduce the impact of biofilm-based infections in human health, provide the following update. In advance of the forthcoming Appendix 4C and quarterly activity report, Next Science notes continuing improvement in the performance of the business across the quarter-to-date. Next Science advises, that with a few days left in the month, unaudited product sales for 2QFY23 are expected to be above USD 5.6 million. This compares with reported product sales of USD 4.4 million in 1QFY23. As the period for 1HFY23 is about to close, it is clear, that Next Science is on track to substantially exceed product sales in 1HFY22 (USD 5.2 million) and 2HFY22 (USD 6.1 million). This is due to the increased investment in sales and marketing that will continue during the establishment phase of the direct sales model for key products.공시 • Jun 17+ 1 more updateNext Science Limited Announces Executive ChangesNext Science Limited announced the appointment of Harry Thomas Hall, IV (commonly known as I.V.) as its new Managing Director and Chief Executive Officer (CEO). I.V. will commence as CEO on 10 July 2023. To ensure a comprehensive and smooth handover, current CEO, Judith Mitchell, will remain with the company until the end of July. New CEO - Harry Thomas Hall, IV (I.V.): Over the course of 28 years in the global medical device industry, I.V. has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. I.V. joined DePuy Synthes, a subsidiary of Johnson and Johnson in 1997 where he held senior roles including: Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. I.V. was most recently a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes and completed the launch of the first surgical robot developed by JNJ /DePuy Synthes. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V. was responsible for a global portfolio and execution strategy for a USD 3.2 billion platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, I.V. created and sustained personal relationships with well over one hundred key opinion leaders worldwide. I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School. I.V. will be relocating from Pennsylvania to be permanently based in Jacksonville, Florida.공시 • Feb 10+ 4 more updatesNext Science Limited to Report Q2, 2023 Results on Jul 31, 2023Next Science Limited announced that they will report Q2, 2023 results on Jul 31, 2023지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 NXSC.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: NXSC.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Next Science 배당 수익률 vs 시장NXSC.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NXSC.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Medical Equipment)2.2%분석가 예측 (NXSC.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NXSC.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NXSC.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NXSC.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: NXSC.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/19 03:52종가2026/02/17 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Next Science Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 11Next Science Limited to Report Q1, 2025 Results on Apr 24, 2025Next Science Limited announced that they will report Q1, 2025 results on Apr 24, 2025
공시 • Mar 11Next Science Limited, Annual General Meeting, May 09, 2025Next Science Limited, Annual General Meeting, May 09, 2025.
공시 • Feb 07Next Science Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Next Science Limited announced that they will report fiscal year 2024 results on Feb 28, 2025
공시 • Jan 20Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025Next Science Limited announced that they will report Q4, 2024 results on Jan 23, 2025
공시 • Jan 08Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former EmployeeNext Science Limited announced that a former employee, Michael Morello has filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging breaches of fiduciary duties and mismanagement against several employees. Mr. Morello was VP, Wound Care Sales at Next Science LLC until December 2023. In May 2024, Next Science LLC commenced litigation against Mr. Morello and several former employees for breach of post-employment restraints. Mr. Morello's complaint makes several claims including that Next Science's XBIO technology has not been approved by the FDA as a biofilm eradication process and that the Company did not take adequate measures to address safety concerns about the use of its surgical solution XPERIENCETM in breast implant procedures. The Company confirms that the products it sells are safe, effective, approved by the FDA (the US healthcare regulatory authority) and promoted within their FDA approved intended use. The Board is concerned that the Complaint has not been brought in good faith due to the fact that Mr. Morello has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged. Next Science has, in consultation with its insurers, engaged US attorneys in relation to both proceedings and the Company and Next Science LLC will continue to pursue the Non- Compete Action against Mr. Morello and several former employees for the breach of post- employment restraints. Next Science will provide further updates as and when there is material progress in these USA civil proceedings.
공시 • Oct 16Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024Next Science Limited announced that they will report Q3, 2024 results on Oct 22, 2024
공시 • Jul 26Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024Next Science Limited announced that they will report first half, 2024 results on Aug 30, 2024
공시 • Jul 10Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024Next Science Limited announced that they will report Q2, 2024 results on Jul 25, 2024
공시 • Apr 23Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024Next Science Limited announced that they will report Q1, 2024 results on Apr 24, 2024
공시 • Mar 04Next Science Limited, Annual General Meeting, May 03, 2024Next Science Limited, Annual General Meeting, May 03, 2024, at 10:01 E. Australia Standard Time.
공시 • Feb 16Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024Next Science Limited announced that they will report fiscal year 2023 results on Feb 28, 2024
공시 • Nov 01Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,571,429 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,851,024 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,244,504 Price\Range: AUD 0.42 Transaction Features: Reserved Share Offering; Subsequent Direct Listing
공시 • Oct 24Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive DirectorNext Science Limited announced the appointment of Ms. Katherine Ostin as an independent Non Executive Director of the Company and Chair of the Board’s Audit and Risk Committee with effect from 24 October 2023. Ms. Ostin is an experienced non-executive director and audit and risk committee chair. Ms. Ostin’s appointment strengthens the Board’s skills in a number of key areas including finance and accounting, audit, risk, governance, strategy and business development. Ms. Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in the aged care and healthcare sectors, having established and led KPMG’s New South Wales Health, Ageing and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms. Ostin worked in Australia, the US, Asia, and the UK. Ms. Ostin currently serves as a Non-Executive Director of 3P Learning Limited, dusk Group Limited, Capral Limited and Alex Corporation Limited. She holds a Bachelor of Commerce (Accounting and Finance) from the University of New South Wales and is a Fellow of the Financial Services Institute of Australasia. Ms. Ostin is also a graduate of the Australian Institute of Company Directors (AICD).
공시 • Aug 23Next Science Limited Announces Board ChangesNext Science Limited announced the appointment of Ms. Aileen Stockburger as Chair of the Next Science Board of Directors and the appointment of a long standing advisor to the Company, Mr. Grant Hummel, as an independent Non-Executive Director, effective 23 August 2023, further strengthening the skills of the Board in a number of key areas including strategy, financial acumen, legal and governance. The timing of the Board changes has been brought about following the retirement of Mr. Mark Compton AM as Chair of the Company. Mr. Compton’s retirement from the Board follows two recent close family bereavements and his need to take some personal time. Aileen Stockburger has been an independent Non-Executive Director of the Company since 2018, having joined ahead of the Company’s admission to ASX. Ms Stockburger was most recently re-elected by shareholders at the Company’s 2023 Annual General Meeting. Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Ms Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania and is a Certified Public Accountant (CPA USA). She is a Non-Executive Director of Microbot Medical and two private equity companies - Orchid Orthopaedic Solutions and Materna Medical. Ms Stockburger is also a graduate of the Australian Institute of Company Directors (AICD). Grant Hummel was part of the Company’s initial public offering (IPO) and ASX listing deal team in 2019. Mr. Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr. Hummel has been a non-executive director of GLG Corp. Ltd. since 2018 and serves as the Chair of GLG’s Nomination and Remuneration Committee and as a member of GLG’s Audit and Risk Committee. Mr. Hummel holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. He also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan). Mr. Hummel has also been appointed as a member of the Board's Audit and Risk Committee and People, Culture and Remuneration Committee. Ms. Stockburger will remain as Chair of the Board's Audit and Risk Committee and independent Non-Executive Director, Mr. DanSpira, will continue to Chair the Board's People, Culture and Remuneration Committee. The Board will continue its ongoing search for at least one new independent non-executive director who may be US based.
공시 • Jun 30+ 1 more updateNext Science Limited Appoints Marc Zimmerman as Chief Financial OfficerThe Board of Next Science Limited appointment and commencement of Marc Zimmerman as Chief Financial Officer.
공시 • Jun 29Next Science Limited Commercialising Its Proprietary Xbiotm Suite of ProductsNext Science Limited announced commercialising its proprietary XBIOTM suite of products to reduce the impact of biofilm-based infections in human health, provide the following update. In advance of the forthcoming Appendix 4C and quarterly activity report, Next Science notes continuing improvement in the performance of the business across the quarter-to-date. Next Science advises, that with a few days left in the month, unaudited product sales for 2QFY23 are expected to be above USD 5.6 million. This compares with reported product sales of USD 4.4 million in 1QFY23. As the period for 1HFY23 is about to close, it is clear, that Next Science is on track to substantially exceed product sales in 1HFY22 (USD 5.2 million) and 2HFY22 (USD 6.1 million). This is due to the increased investment in sales and marketing that will continue during the establishment phase of the direct sales model for key products.
공시 • Jun 17+ 1 more updateNext Science Limited Announces Executive ChangesNext Science Limited announced the appointment of Harry Thomas Hall, IV (commonly known as I.V.) as its new Managing Director and Chief Executive Officer (CEO). I.V. will commence as CEO on 10 July 2023. To ensure a comprehensive and smooth handover, current CEO, Judith Mitchell, will remain with the company until the end of July. New CEO - Harry Thomas Hall, IV (I.V.): Over the course of 28 years in the global medical device industry, I.V. has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. I.V. joined DePuy Synthes, a subsidiary of Johnson and Johnson in 1997 where he held senior roles including: Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. I.V. was most recently a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes and completed the launch of the first surgical robot developed by JNJ /DePuy Synthes. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V. was responsible for a global portfolio and execution strategy for a USD 3.2 billion platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, I.V. created and sustained personal relationships with well over one hundred key opinion leaders worldwide. I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School. I.V. will be relocating from Pennsylvania to be permanently based in Jacksonville, Florida.
공시 • Feb 10+ 4 more updatesNext Science Limited to Report Q2, 2023 Results on Jul 31, 2023Next Science Limited announced that they will report Q2, 2023 results on Jul 31, 2023